Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion

H. Cody Meissner, William J. Rodriguez, S A Chartrand et al.|The Pediatric Infectious Disease Journal|1999

Cited by 129